U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284797) titled 'A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Idiopathic Inflammatory Myopathy (IIM)' on Dec. 03.
Brief Summary: The purpose of this study is to determine the safety and tolerability of XmAb657 in healthy participants and participants with IIM. Participants will be given XmAb657 subcutaneously (SC) by injection under the skin.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy
Idiopathic Inflammatory Myopathies
Intervention:
BIOLOGICAL: XmAb13676
Biological
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Xencor, Inc.
Published by HT Digital Content Servi...